FULC Q2 2023 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FULCFulcrum Therapeutics, Inc.

$436M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$880,000-53.2% YoY

Gross Profit

-$17M-1928.3% margin

Operating Income

-$27M-3101.4% margin

Net Income

-$24M-2702.6% margin

EPS (Diluted)

$-0.38

QoQ Revenue Growth

+198.3%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$21M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$300M

Total Liabilities

$25M

Stockholders' Equity

$275M

Cash & Equivalents

$34M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$880,000	$2M	-53.2%
Gross Profit	-$17M	-$23M	+26.7%
Operating Income	-$27M	-$34M	+20.3%
Net Income	-$24M	-$34M	+30.2%